Journal
GENETICS IN MEDICINE
Volume 20, Issue 6, Pages 622-629Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/gim.2017.156
Keywords
CNVs; drug pharmacokinetics; novel gene deletions; personalized medicine; pharmacogenes
Categories
Funding
- Spanish Ministry of Economy and Competiveness [SAF2015-64850-R]
- European Union [668353]
- Swedish Research Council [2015-02760, 2016-01153, 2016-01154]
Ask authors/readers for more resources
Purpose: Variability in pharmacokinetics and drug response is shaped by single-nucleotide variants (SNVs) as well as copy-number variants (CNVs) in genes with importance for drug absorption, distribution, metabolism, and excretion (ADME). While SNVs have been extensively studied, a systematic assessment of the CNV landscape in ADME genes is lacking. Methods: We integrated data from 2,504 whole genomes from the 1000 Genomes Project and 59,898 exomes from the Exome Aggregation Consortium to identify CNVs in 208 relevant pharmacogenes. Results: We describe novel exonic deletions and duplications in 201 (97%) of the pharmacogenes analyzed. The deletions are population-specific and frequencies range from singletons up to 1%, accounting for > 5% of all loss-of-function alleles in up to 42% of the genes studied. We experimentally confirmed novel deletions in CYP2C19, CYP4F2, and SLCO1B3 by Sanger sequencing and validated their allelic frequencies in selected populations. Conclusion: CNVs are an additional source of pharmacogenetic variability with important implications for drug response and personalized therapy. This, together with the important contribution of rare alleles to the variability of pharmacogenes, emphasizes the necessity of comprehensive next-generation sequencing-based genotype identification for an accurate prediction of the genetic variability of drug pharmacokinetics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available